Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis.

Abstract

To access the efficacy of antiviral therapy in patients of HBV-infected with immune-tolerant. We conducted a meta-analysis search of the Cochrane Library, PubMed, ClinicalTrials.gov, Web of science, and EMBASE on through August 2021. We combined the data by means of a random-effect DrSimonian-Laird model and calculated risk ratios (RRs) for the outcomes of hepatitis B surface antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) seroconversion, HBV deoxyribonucleic acid (DNA) negative conversion rate, and the risk for hepatocellular carcinoma (HCC) and cirrhosis. An extensive literature search identified 328 relevant publications, and five were included in the study. Antiviral therapy was in favor of HBsAg loss (RR=2.34, 95%CI 0.68-4.00, p=0.91, I2=0.00%), HBV DNA negative conversion (RR=2.08, 95%CI 0.10-4.05, p=0.07, I2=58.24%) and reduce the risk for HCC (HR=0.189, 95%CI 0.052-0.692, p=0.004) and cirrhosis (HR=0.347, 95%CI 0.095-1.270, p=0.036), but not beneficial to HBeAg seroconversion (RR=0.83, 95%CI -0.03 to 1.70, p=0.11, I2=46.99%). Subgroup-analyzed by the research type was similar results of HBsAg loss, HBV DNA negative conversion, and HBeAg seroconversion.Patients in HBV-infected with immune-tolerant responded well to antiviral therapy. The evidence from this meta-analysis supports antiviral therapy for patients with HBV in the immune tolerance stage. Well-designed, multi-center, larger sample sizes, and excellent quality prospective studies are needed to confirm our conclusion.

• Authors: Ji Huang, Yongqi Liu, Youshun Liu
• Journal: Gastroenterologia y hepatologia (Gastroenterol Hepatol) Vol. 46 Issue 4 Pg. 309-318 (Apr 2023) ISSN: 0210-5705 [Print] Spain
• PMID: 35700836 (Publication Type: Meta-Analysis, Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

Chemical References

• Antiviral Agents
• Hepatitis B Surface Antigens
• Hepatitis B e Antigens
• DNA, Viral

Topics

• Humans
• Hepatitis B virus (genetics)
• Antiviral Agents (therapeutic use)
• Hepatitis B Surface Antigens
• Hepatitis B, Chronic (complications, drug therapy)
• Hepatitis B e Antigens
• Carcinoma, Hepatocellular
• DNA, Viral
• Liver Neoplasms (drug therapy)
• Liver Cirrhosis (etiology, chemically induced)